EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tadalafil as an adjunct therapy in primary end-to-end urethroplasty for PFUI: A clinical evaluation

Navdeep Garg, Sanjeev Jaiswal, Somendra Bansal, Sudeep Singh, Nachiket Vyas, Shivam Priyadarshi

International Journal of Reconstructive Urology · 2026-01 · 4 (1) · 92-95

DOI: 10.4103/ijru.ijru_42_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Reconstructive Urology, online erschienen am 27.04.2026. Verfasst von Navdeep Garg und 5 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pelvic fracture urethral injuries (PFUI) often lead to erectile dysfunction (ED) and recurrent urethral strictures due to fibrosis post-urethroplasty. Tadalafil, commonly used for treating ED, has demonstrated antifibrotic properties in animal studies. This study evaluates the efficacy of tadalafil in improving surgical outcomes in PFUI urethroplasty in humans. Materials and Methods: A prospective study was conducted on 40 male patients undergoing urethroplasty for PFUI from January 2023 to January 2024. Patients were divided into two groups: Group 1 ( n = 20) received 5 mg tadalafil daily postoperatively for 3 months, while Group 2 ( n = 20) did not receive tadalafil. Outcomes were assessed based on the success rate (symptom resolution and no need for further intervention) and complication rates.

Results

The tadalafil group had a higher success rate (80%) compared to the non-tadalafil group (60%), with fewer complications (20% vs. 40%, P < 0.05). Redo urethroplasty and dilatation rates were also lower in the tadalafil group.

Conclusion

Postoperative use of tadalafil significantly improved surgical outcomes in PFUI urethroplasty by reducing fibrosis and complications. Tadalafil may serve as a promising adjunct in urethral reconstruction, though larger studies are recommended to confirm these findings.

Zitieren

APA

Garg, N., Jaiswal, S., Bansal, S., Singh, S., Vyas, N., & Priyadarshi, S. (2026). Tadalafil as an adjunct therapy in primary end-to-end urethroplasty for PFUI: A clinical evaluation. International Journal of Reconstructive Urology, 4(1), 92-95. https://doi.org/10.4103/ijru.ijru_42_25

Vancouver

Garg N, Jaiswal S, Bansal S, Singh S, Vyas N, Priyadarshi S. Tadalafil as an adjunct therapy in primary end-to-end urethroplasty for PFUI: A clinical evaluation. International Journal of Reconstructive Urology. 2026;4(1):92-95. doi:10.4103/ijru.ijru_42_25

BibTeX
@article{Garg2026,
  author = {Garg, Navdeep and Jaiswal, Sanjeev and Bansal, Somendra and Singh, Sudeep and Vyas, Nachiket and Priyadarshi, Shivam},
  title = {Tadalafil as an adjunct therapy in primary end-to-end urethroplasty for PFUI: A clinical evaluation},
  journal = {International Journal of Reconstructive Urology},
  year = {2026},
  volume = {4},
  number = {1},
  pages = {92--95},
  doi = {10.4103/ijru.ijru_42_25}
}
Kostenlos starten →